3-(3-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid

• ChemBase编号: 72671
• 分子式: C25H22N4O4
• 平均质量: 442.46658
• 单一同位素质量: 442.1641052
• SMILES: c1c(c(c(cc1)c1cccc(c1)C(=O)O)O)N/N=C\1/C(=O)N(N=C1C)c1ccc(c(c1)C)C
• Canonical SMILES: OC(=O)c1cccc(c1)c1cccc(c1O)N/N=C/1\C(=NN(C1=O)c1ccc(c(c1)C)C)C
• InChI: InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22+
• InChIKey: XDXWLKQMMKQXPV-HPNDGRJYSA-N

名称和登记号

名称

• IUPAC标准名: 3-(3-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid
• IUPAC传统名: eltrombopag
• 别名: SB-497115-GR; Revolade; Promacta; Eltrombopag

登记号

• CAS号: 496775-61-2
• PubChem SID: 162037592
• PubChem CID: 9846180

理论计算性质

• Acid pKa: 3.9870398
• 质子受体: 7
• 质子供体: 3
• LogD (pH = 5.5): 4.5041704
• LogD (pH = 7.4): 2.8513787
• Log P: 6.0262365
• 摩尔折射率: 126.4827 cm^3
• 极化性: 47.734787 Å^3
• 极化表面积: 114.59 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: false

分子性质

安全信息

• 保存条件: -20°C

药理学性质

• 作用靶点: TpoR

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S2229

Research Area: Cancer
Biological Activity:
Eltrombopag (SB-497115-GR, Promacta, Revolade) is a small molecule agonist of the c-mpl (TpoR) receptor with an IC50 of 0.69 μM for the inhibition of hERG K+ channel tail current. In preclinical studies, the compound was shown to interact selectively with the thrombopoeitin receptor, leading to activation of the JAK-STAT signaling pathway and increased proliferation and differentiation of megakaryocytes. Animal studies confirmed that administration could increase platelet counts.In addition, eltrombopag (SB-497115-GR, Promacta, Revolade) decreased proliferation of all cancer cell lines. [1][2]

参考文献

• Erickson-Miller CL et al. Leuk Res. 2010 Sep;34(9):1224-31.